Pharma R&D
Pharma R&D
Pharma R&D
Pharma R&D
Directors & Senior Staff
Bernie Romanin
Chief Executive Officer and Director
B App Sci and Grad Dip Marketing
Bernie Romanin has extensive healthcare experience in Diagnostics, Pharmaceuticals, Healthcare Bioinformatics and Medical Devices gained in Australia and internationally including commercial expertise (sales, marketing and business development) spanning more than 35 years.
During almost a decade in the USA with Chiron, Novartis and Bayer he has directed market development activities to identify, validate and commercialise new opportunities in diagnostics in the areas of Infectious Diseases (Hepatitis and HIV/AIDS), Oncology, Cardiovascular Disease and Metabolic Disorders.
Bernie has significant experience in managing start-up and new market business opportunities particularly in Technology Licensing and Partnerships and broad experience in managing a multi-functional organisation including R&D, sales and marketing, business development and market research.
Dr. Robyn A. Lindley
Chief Scientific Officer, Director and Founder
Inventor and Developer of the TSM Platform.
BSc, MInfoTech, PhD
Dr Robyn A. Lindley is a Founder, Director and the Chief Scientific Officer of GMDx Genomics, Melbourne. She is also an Honorary Principal Fellow in the Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.
Although her first degrees are in physics and informatics, Robyn is an immunogeneticist who has been publishing on the relationships between inflammation, disease progression and somatic mutation signatures. Robyn is the sole discoverer of the specific codon-contexted targeted somatic mutation (TSM) signatures of nucleotide-specific deaminase enzymes that are now heavily implicated in many cancers. She was also the first to show that some of these changes can be used to predict cancer progression. She was the recipient of the RD Wright medal in 2016, University of Melbourne, for 'marching to the beat of her own drum'. Robyn's foundation research is now being used to develop new genetic tests to predict patient response to
immuno-oncology drugs and cancer progression for use in the North American market.
Matt Kilpatrick
Non-Executive Director and Founder
A talented C-Suite executive, senior advisor and successful entrepreneur, Matt has enjoyed a business career spanning over 35-years. A strategic and astute business leader that has undertaken an extensive number of business development and advisory roles within multiple industry and technology sectors.
Recognised as a personable and hands-on business leader, Matt’s comprehensive corporate experience and capacious business acumen has added substantial value across wide range of commercial situations from start-ups to established organisations looking for scale.
Matt has successfully led multiple capital raising campaigns and attracting both private and public equity investing. He is highly capable of leading organisations in both strategy & execution to complete a Listing, IPO, Trade Sale or M&A outcome and brings a creative and dynamic leadership approach to every project. He is able to add significant value and provide strategic leadership in diverse commercial scenarios whether during times of organisational growth or crisis.
Richard Rendell
Non-Executive Director
An accomplished Melbourne-based company director and CEO with 18 year’s experience in healthcare, precision medicine, life-sciences, information technology, M&A, investment, commercialisation, globalisation and compliance. Richard has recently been covered in Forbes magazine regarding his company Applied Precision Medicine, one of a portfolio of 4 companies he has created over a 7 year period. His success in Healthcare, Medical Device, and Digital Health sectors showcases an ability to identify and pursue emerging markets using proven adaptive business models under strong compliance and governance. At Oracle Corporation, Richard owned several product divisions with responsibility for global strategy in sales, marketing, consulting, product development, education and support. He led technical and commercial due diligence in many Oracle acquisitions. Richard is also media trained and has worked with journalists in the United States and Australia. Richard was an advisory board founder at iSelect Pty Ltd where he returned in 2008 as CIO to deliver significant business restructuring to support new insurance markets building iSelect’s next chapter in digital strategy. iSelect listed on the ASX in June 2013 at a value of AU$300M.
Tim Luscombe
Chief Financial Officer & Company Secretary
CFO
Tim holds a Bachelor of Commerce from the University of Melbourne and is a highly experienced Chartered Accountant who brings professional skills gained in both public practice accounting and the corporate sector. After 4 years in a mid-tier accounting practice, in 2018 Tim decided to broaden his skill base and to enjoy some travel by relocating to London where he worked within the finance teams of various large companies most notably The Football Association (The FA). Returning in 2020 and joining the Bio101 team as an Outsourced CFO, Tim provides strategic advice to management and boards on financial reporting, cash forecasting, direct and indirect taxes, governance and management matters.
Dr. Nathan Hall
Genomics & Platform Lead
Senior Scientist
BSc(Hons), PhD
Dr. Nathan Hall is an accomplished researcher with expertise in bioinformatics, computational biology and genomics sciences. His background is in biomedical research, starting out his career over twenty years ago when genomes were only beginning to be sequenced. Nathan collaborates widely and is published in areas such as Cancer research and genomic analyses.
Nathan understands the importance of integrating computational biology with medical and scientific research to maximise the benefits of modern sequencing technologies. With this understanding of the power of genomic technology, Nathan is engaging with Medical Practitioners, laboratory scientist and researchers, and computational professionals to bring together a platform for genomic testing moving into the future.
Dr. Jared Mamrot
Bioinformatician
BSc(Hons), MCE, PhD
Dr. Mamrot is a bioinformatician/data scientist who completed his PhD in developmental genomics at the Hudson Institute of Medical Research in Victoria, Australia. He has experience developing novel computational pipelines and applying innovative methods to complex biological challenges. He is an active member of the scientific community and is an ambassador for reproducibility and open science initiatives for the journal eLife and protocols.io.
At GMDx, he is applying state-of-the-art artificial intelligence / machine learning methods to drive scientific advances in immunology and oncology. He is currently heading the machine learning program developing novel approaches to predict patient response to treatments for many diseases.
Advisors
Mike Webb
Advisor
An accomplished and senior life science’s professional advisor with over 30 years’ experience deploying significant expertise in taking early-stage companies forward through to commercial maturity.
Appointed to numerous Chairman, Board and CEO positions in start-up companies through to NASDAQ listings. Provided significant commercialisation and commercial advancement contributions to the health care industry. Such contributions have included providing expert advisory to pharma, diagnostics and life sciences companies. Previous engagements include Novartis Diagnostics, EPIX Pharmaceuticals, Tyrogenex and Booz, Allen & Hamilton.
Dr. Katherine Tyne
Senior Advisor (USA)
A mission-driven healthcare strategist who works on inspiring business growth through critical thinking and strategic development with the intent to save and improve lives. As a 15+ year executive consultant, she is a highly sought-after Advisor who works closely with CEOs, BODs and investors to help companies reach their potential.
Additionally, as a recognized thought leader in healthcare & clinical diagnostics. Katherine advises venture investors and Fortune 500 companies on their mergers and acquisitions, healthcare strategy and investments. Katherine has held multiple management and executive roles in public and private companies. Since founding her own consulting practice she has been involved in over $1B of risk capital investments in the precision medicine arena.
Dr. Steve Averbuch
Senior Advisor-Oncology (USA)
An industry veteran with more than 35 years in oncology drug development and more than a decade in biomarker and drug diagnostic co-development, Dr. Steven D. Averbuch has contributed to multiple drug and companion diagnostic approvals in the U.S. and other major markets.
Formerly at Bristol-Myers Squibb (BMS) he led integrated biomarker and pharmacodiagnostic activities across the company’s R&D portfolio. During his tenure, Dr. Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, established in 2008, which led to the application of BMS’ precision medicine strategy across all therapeutic areas. Under his leadership, the Center integrated the co-development and co-commercialization of diagnostic tests as companions to BMS medicines. Previously, Dr. Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine and served as the Head of Early Global Clinical Research, where he was responsible for early asset development strategy and execution of all Phase 2 oncology programs.
He has served in leadership roles at Merck Research Laboratories and at AstraZeneca. He is a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research.